Who are rhTSH's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Recombinant LH (Luveris), rhTSH stimulation, Thyrogen + Radioiodine (131I), Recombinant choriogonadotropin alfa.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rhtsh.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

rhTSH — Competitive Intelligence Brief

rhTSH (rhTSH) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant hormone. Area: Oncology; Endocrinology.

marketed Recombinant hormone TSH receptor (TSHR) Oncology; Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

rhTSH (rhTSH) — Gustave Roussy, Cancer Campus, Grand Paris. rhTSH (recombinant human thyroid-stimulating hormone) stimulates the thyroid gland to produce and release thyroid hormones.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
rhTSH TARGET	rhTSH	Gustave Roussy, Cancer Campus, Grand Paris	marketed	Recombinant hormone	TSH receptor (TSHR)
Recombinant LH (Luveris)	Recombinant LH (Luveris)	Azienda Ospedaliero-Universitaria di Modena	marketed	Gonadotropin; recombinant hormone	Luteinizing hormone receptor (LHCGR)
rhTSH stimulation	rhTSH stimulation	Gustave Roussy, Cancer Campus, Grand Paris	phase 3	Recombinant hormone	TSH receptor
Thyrogen + Radioiodine (131I)	Thyrogen + Radioiodine (131I)	Genzyme, a Sanofi Company	phase 3	Recombinant hormone + radiopharmaceutical combination	TSH receptor (TSHR)
Recombinant choriogonadotropin alfa	Recombinant choriogonadotropin alfa	Instituto de Investigacion Sanitaria La Fe	phase 3	Gonadotropin; recombinant hormone	Luteinizing hormone receptor (LH-R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant hormone class)

Gustave Roussy, Cancer Campus, Grand Paris · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rhTSH — Competitive Intelligence Brief. https://druglandscape.com/ci/rhtsh. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab